Iomeron

Iomeprol, the active ingredient in Iomeron, is an iodinated contrast media presented as an injectable solution for intra‑arterial, intrathecal, and intravenous use. It creates radiodense contrast that enhances visualization of vascular and tissue structures during diagnostic imaging procedures in clinical practice.

GNH USA supplies Iomeron as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to stringent quality standards and regulatory requirements. The company serves hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable access to this essential imaging agent.

Iomeprol is employed as a radiographic contrast agent to improve the delineation of anatomical structures during various imaging examinations. - Angiography: enhances visualization of blood vessels, facilitating accurate assessment of vascular patency and lesions. - Computed tomography (CT) imaging: provides high‑contrast enhancement of organs and tissues for detailed cross‑sectional images. - Urography: improves delineation of the urinary tract, aiding detection of obstructions or structural abnormalities. - Arthrography: increases contrast within joint spaces, allowing precise evaluation of cartilage and intra‑articular structures. - Myelography: supplies clear contrast of the spinal canal and nerve roots for diagnostic assessment. - Contrast‑enhanced radiographic examinations: augments overall image quality across a range of X‑ray based studies.

Iomeprol may be associated with a range of adverse reactions, varying from mild and transient to severe and life‑threatening.

Common Side Effects: - Warmth or flushing sensation at the injection site, typically lasting a few seconds to minutes. - Metallic taste or transient oral tingling that resolves shortly after administration. - Mild nausea, vomiting, or headache occurring within the first hour post‑injection.

Serious or Rare Side Effects: - Severe allergic or anaphylactoid reactions, including bronchospasm, urticaria, and possible anaphylaxis requiring emergency treatment. - Acute kidney injury, particularly in patients with pre‑existing renal impairment or dehydration, which may necessitate renal monitoring. - Cardiovascular events such as marked hypotension, arrhythmia, or cardiac arrest, especially in high‑risk individuals.

Prior to administering Iomeprol, clinicians should observe several precautionary measures to minimize risk and ensure patient safety. - Assess renal function: evaluate serum creatinine and eGFR before use. - Review allergy history: identify prior reactions to iodinated contrast or iodine‑containing substances. - Use the lowest effective dose: tailor volume to the specific imaging requirement. - Monitor vital signs: observe blood pressure, heart rate and oxygen saturation during and after injection. - Avoid in patients with known iodine hypersensitivity: consider alternative imaging agents. - Store at ambient temperature: keep the vial in the original packaging, protect from light and moisture.

Iomeprol can interact with certain medications, affecting safety or efficacy; awareness of these interactions helps guide clinical decisions.

Major Interactions (Avoid): - Concurrent nephrotoxic drugs (e.g., aminoglycosides, high‑dose NSAIDs): increase risk of contrast‑induced renal injury. - Metformin in patients with impaired renal function: may precipitate lactic acidosis; discontinue before and after contrast administration. - Thyroid hormone therapy: iodinated contrast can alter thyroid function tests and exacerbate hyperthyroidism.

Moderate Interactions (Monitor Closely): - Diuretics: may affect fluid balance and heighten risk of hypotension during contrast injection. - Beta‑blockers: can mask tachycardia that sometimes follows contrast‑induced anaphylactoid reactions.